Biognosys’ novel Drug Target Validation service offers a unique way to confidently characterize a drug’s binding site and de-risk early drug development. By using our High Resolution Limited Proteolysis (HR-LiP) technology coupled with Mass Spectrometry, we remove the need for molecule tagging, protein modifications, or recombinant proteins. All we need is a cell line overexpressing your target of interest and a stock of your compound.
Validating the target of a small molecule compound is key to both de-risking research pipelines and shortening a drug’s time to market. It can be achieved by confidently characterizing the compound’s binding site in its protein target. This provides valuable insights that can guide compound optimization.
Our Drug Target Validation solution is part of our TrueTarget™ platform offering. Biognosys’ TrueTarget platform uses peptide-level information to enable both drug target deconvolution (LiP-MS) and further compound binding site characterization (HR-LiP) in a label-free manner. Collectively, these technologies empower drug discovery and optimization.
The Drug Target Validation service can be performed on every kind of protein from all species in a near-native environment. Furthermore, traditionally difficult-to-characterize proteins, such as those with a high molecular mass or membrane localization, can be analyzed in their full length.
In contrast to conventional structural biology techniques such as crystallography, our Drug Target Validation service leverages structural proteomics and offers a cost-efficient alternative with a few weeks of project turnaround time.
“We had previously enlisted other methods for target deconvolution and validation for our molecular glue program at the global protein structural readout level, including small molecule selectivity in cells. Biognosys’ TrueTargetTM (LiP-MS) platform provided a proteome-wide picture of our glue with peptide-level resolution. Analogous to HDX-MS on recombinant proteins, TrueTarget™ (LiP-MS) simultaneously provided information about conformational changes and small molecule binding sites in cells within one experiment. With Biognosys’ high-quality data and bioinformatics support, we could draw conclusions about endogenous target binding and compound selectivity, moving our program forward with high confidence.”
Maria Stella Ritorto, PhD
Director of Proteomics at Nested Therapeutics, Cambridge, MA
“Biognosys’ TrueTarget platform was instrumental in identifying our target protein’s binding site and in this way provided valuable mechanistic insights that helped us to understand the underlying biology of our observed phenotype.”
Prof. David Rubinsztein
Professor of Molecular Neurogenetics, UK Dementia Research Institute Group Leader at the University of Cambridge, and Deputy Director of the Cambridge Institute for Medical Research.
Learn more about Biognosys’ proprietary TrueTarget™ platform in our latest brochure. This resource elaborates on how TrueTarget™ identifies the most promising and actionable [...]
Wrobel L. et al. Nature Communications Enhancing the removal of aggregate-prone toxic proteins is a rational therapeutic strategy for a number of neurodeg [...]
The results are presented and discussed with you in a seminar or webinar and delivered electronically in PDF and Excel formats.
Peptide intensities across dose-response treatment
a) Protein target candidate peptides ranked by dose-response correlation
b) Compound affinity concentration for each peptide candidate
c) Mapping of peptide candidates and predicted binding location on tertiary protein structures if available
Drug Target Validation is applicable to complex biological matrices, including a wide variety of cell lines and organisms.
Biognosys is committed to providing the best possible results to our customers at the fastest possible project turnaround time.